高剂量重组人红细胞生成素冲击治疗恶性肿瘤贫血的临床应用及护理  

Clinal application and nursing of high-dose recombinant human erythropoietin in treatment of a-nemic patients with malignancies

作　　者：何艳艳[1] 孙衍伟[2] 康丛利[3] 

机构地区：[1]山东省日照市人民医院急诊科,276826 [2]山东省日照市人民医院肿瘤科,276826 [3]山东省日照市人民医院检验科,276826

出　　处：《中国实用医刊》2013年第4期95-97,共3页Chinese Journal of Practical Medicine

摘　　要：目的观察高剂量重组人红细胞生成素（RHEpo）冲击治疗恶性肿瘤贫血的临床疗效及不良反应。方法将86例恶性肿瘤贫血患者随机分为对照组（RHEpo1万U，每周3次，共6周）与高剂量组（RHEpo4万U／次，第1、3天，RHEpo2万U／次，第6、9、12、15、18、21、24天）。治疗期间加强患者心理护理，合理用药，严密观察病情，及时处理并发症。所有患者共观察6周，每2周进行1次疗效评价，评价指标包括患者的血红蛋白值、有效率、输血率、停药者比率及药物的不良反应。结果对照组4周后血红蛋白值明显升高，高剂量组治疗2周后血红蛋白值明显升高；高剂量组的4、6周血红蛋白值均高于对照组（P〈0．05）；高剂量组的2、4、6周有效率分别为40．5％、54．8％、71．4％，高于对照组的19％、28．6％、50．0％（P〈0．05）；两组输血率及不良反应率比较差异无统计学意义（P〉0．05）。结论高剂量RHEpo冲击治疗恶性肿瘤贫血的疗效优于常规剂量法，不良反应无明显增加，合理护理是RHEpo充分发挥疗效的关键。Objective To study the clinical effect and side effect of high-dose recombinant hu- man erythropoietin （RHEpo）on anemic patients with malignancies. Methods Eighty-six anemic patients with malignancies were randomly divided into matched group （rhEPO 10 000 U were administered three times weekly for up to six weeks） or tJigh-dose group（ the specific use for the first 1,3 days for erythropoi- etin 40 000U, and then in the first：6, 9,12,15,18,21,24 days given erythropoietin 20 000U every day）. Strengthen psychological nursing, rational use of drugs, condition observation, management of complications during the course of treatment. The patients were observed for 6 weeks, and evaluated ev- ery 2 weeks. The evaluation indexes including hemoglobin value, efficient rate, blood transfusion rate, the ratings and adverse reaction. Results Hemoglobin level of high-dose group increased significantly after treatment of 2 weeks, while that of matched group increased significantly after treatment of 4 weeks. The main hemoglobin level in high-dose group was higher than those in matched group after treatment of 4 and 6 weeks（ P 〈 0. 05）. The effect rates of 2,4,6 weeks were 40. 5% ,54. 8% ,71.4% respectively in high-dose group, higher than 19% ,28.6% ,50. 0% respectively in matched group（ P 〈0.05）. There were no significant differences in side effect and transfusion rate between the two groups （ P 〉 0. 05 ）. Conclusions The effect of high-dose RHEpo is better than RHEpo with common doses on anemic pa- tients with malignancies. There is no difference in side effect between the two groups. Reasonable care plays an important role in the curative effect of RHEpo.

关 键 词：重组人红细胞生成素 肿瘤 贫血 

分 类 号：R473.6[医药卫生—护理学]